J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Part 3: Scrip spoke with companies working on cell and gene therapies and novel approaches to neurological diseases during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

JPM Roundtable 3

Regulators around the world are helping companies with innovative regenerative medicine platforms and other novel technologies get their medicines to patients as quickly as possible – and prospective investors and partners are taking notice.

Roundtable Participants

BlueRock Therapeutics VP of Corporate Development and Strategy Eric Soller. BlueRock uses induced pluripotent stem cells (iPSCs) to develop engineered cells in the areas of neurology, cardiology and autoimmunity. Lead programs include a dopaminergic neuron for Parkinson's disease moving into the clinic this year, a cardiomyocyte for congestive heart failure, and a macrophage to treat autoimmune diseases. (Also see "Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata" - Scrip, 11 October, 2018.)

United Neuroscience (UNS) CEO Mei Mei Hu. UNS is leveraging vaccine technology commercialized in more than 4bn doses – primarily in animal health – to develop therapeutic vaccines. SC123854 The company recently reported positive Phase IIa data for its lead candidate targeting amyloid beta in Alzheimer's disease. (Also see "United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa" - Scrip, 17 January, 2019.) 

Athersys Chairman and CEO Gil Van Bokkelen. Athersys is developing MultiStem from adult stem cells derived from donated bone marrow and other tissues. It is in Phase III with a regenerative medicine advanced therapies (RMAT) designation from the FDA for ischemic stroke; it's in mid-stage studies for heart attack and acute respiratory distress syndrome. Healios KK holds a license for MultiStem in Japan.

PTC Therapeutics Inc. Chief Scientific Officer Mark Pykett. PTC's portfolio includes the commercial Duchenne muscular dystrophy (DMD) drugs – Emflaza (deflazacort) in the US and Translarna (ataluren) outside the US (estimated combined sales of $280m-$305m in 2019) – and various rare disease and oncology candidates. PTC got into gene therapy by acquiring Agilis Biotherapeutics LLC last year; Pykett was president and CEO of Agilis. Lead gene therapy candidate GT-AADC for aromatic L-amino acid decarboxylase (AADC) deficiency will be submitted for US FDA approval in 2019.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By 

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

More from Business

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By 

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By 

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.